Abuse liability of dextromethorphan and its combinatory formulation dextromethorphan/bupropion: a pharmacologic perspective
The formulation demonstrates clinically meaningful improvement within one week of its initiation. Given its safety and efficacy, alongside its novelty, this glutamatergic modulator represents a promising candidate for approval across global jurisdictions and regions. Future research should examine DXM/BUP's potential efficacy in bipolar depression and trauma-associated MDD, populations exhibiting refractory responses to conventional antidepressants and in need of an alternative, mechanistically distinct therapeutic.
Authors
- Angela T.H. Kwan (ORCID: https://orcid.org/0000-0003-4013-1112)
- Gia Han Le (ORCID: https://orcid.org/0000-0001-6457-0086)
- Roger S. McIntyre (ORCID: https://orcid.org/0000-0003-4733-2523)
- Kayla M. Teopiz (ORCID: https://orcid.org/0000-0001-8429-6563)
- Yang Jing Zheng
- Sabrina Wong (ORCID: https://orcid.org/0009-0002-0928-3433)
- Christine E. Dri
Institutions
- University Health Network (CA)
- University of Ottawa (CA)
- University of Toronto (CA)
- Health Net (US)
- Brain and Cognition Discovery Foundation (CA)
Publication Details
- Journal
- Expert Opinion on Drug Metabolism & Toxicology
- Published
- 2025-12-18
- DOI
- https://doi.org/10.1080/17425255.2025.2607017
- Primary Topic
- Respiratory and Cough-Related Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00